Vunakizumab Injection Application Scope

Vunakizumab Injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. It is a monoclonal antibody targeting interleukin-23 (IL-23), a key cytokine in the pathogenesis of psoriasis. By inhibiting IL-23, Vunakizumab helps to reduce the production of inflammatory cytokines, leading to significant improvement in skin lesions and the reduction of symptoms such as scaling, redness, and thickness in psoriasis.

Vunakizumab Injection Characteristics

Ingredients: Vunakizumab
Properties: Monoclonal antibody targeting IL-23
Packaging Specification: 100 mg/1 mL per vial × 1 vial/box
Storage: Store at 2–8°C; do not freeze; protect from light
Expiry Date: As indicated on packaging (typically 24 months from manufacturing date)
Executive Standard: In accordance with pharmacopoeia and regulatory requirements
Approval Number: As per national drug regulatory authority
Date of Revision: Latest update per product labeling
Manufacturer: As per product packaging

Guidelines for the Use of Andajing

Dosage and Administration:
- Recommended Dose: Initial dose: 300 mg at weeks 0, 4, and then every 8 weeks thereafter (typical regimen for adults)
- Administration: Subcutaneous injection
- Missed Dose: Administer as soon as possible, but do not double the dose to make up for a missed one
Adverse Reactions:
- Common Adverse Reactions: Injection site reactions, upper respiratory tract infections, headache, fatigue
- Serious Adverse Reactions: Hypersensitivity reactions, serious infections, gastrointestinal disorders, liver enzyme abnormalities
Contraindications:
- Known hypersensitivity to Vunakizumab or any component of the formulation
- Active or serious infections (e.g., tuberculosis, fungal infections)
Precautions:
- Monitor for signs of infection during therapy
- Use with caution in patients with a history of recurrent infections or immune system disorders
- Avoid live vaccines during treatment

Vunakizumab Injection Interactions

Limited interaction data available
Avoid co-administration with live vaccines
No significant interactions reported with common medications

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.